Abstract
Childhood tuberculosis (TB) continues to be a neglected disease in areas where limited resources restrict the focus of national TB control programmes to only the most infectious sputum smear-positive cases. However, appreciation that children contribute a significant proportion to the global TB disease burden and suffer severe TB-related morbidity and mortality is growing. The World Health Organization (WHO) published guidelines on the management of paediatric TB in 2006 and child friendly drug formulations have been made available to deserving nations via the Global Drug Facility (GDF) since 2008. These advances also served to emphasize the considerable programmatic barriers that remain in resource- limited settings. This review provides an overview of current treatment practices, presenting the authors personal perspectives on issues related to the treatment of childhood TB, together with a brief synopsis of potential future treatment options.
Keywords: Pediatric tuberculosis, management, treatment, TB, infectious sputum, GDF, current treatment practices, childhood TB, future treatment options, children, bacterial pneumonia, HIV, respiratory disease, first-line antibiotics, endemic areas
Infectious Disorders - Drug Targets
Title: Management of Tuberculosis in Children and New Treatment Options
Volume: 11 Issue: 2
Author(s): B. J. Marais, H. S. Schaaf and P. R. Donald
Affiliation:
Keywords: Pediatric tuberculosis, management, treatment, TB, infectious sputum, GDF, current treatment practices, childhood TB, future treatment options, children, bacterial pneumonia, HIV, respiratory disease, first-line antibiotics, endemic areas
Abstract: Childhood tuberculosis (TB) continues to be a neglected disease in areas where limited resources restrict the focus of national TB control programmes to only the most infectious sputum smear-positive cases. However, appreciation that children contribute a significant proportion to the global TB disease burden and suffer severe TB-related morbidity and mortality is growing. The World Health Organization (WHO) published guidelines on the management of paediatric TB in 2006 and child friendly drug formulations have been made available to deserving nations via the Global Drug Facility (GDF) since 2008. These advances also served to emphasize the considerable programmatic barriers that remain in resource- limited settings. This review provides an overview of current treatment practices, presenting the authors personal perspectives on issues related to the treatment of childhood TB, together with a brief synopsis of potential future treatment options.
Export Options
About this article
Cite this article as:
J. Marais B., S. Schaaf H. and R. Donald P., Management of Tuberculosis in Children and New Treatment Options, Infectious Disorders - Drug Targets 2011; 11 (2) . https://dx.doi.org/10.2174/187152611795589645
DOI https://dx.doi.org/10.2174/187152611795589645 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Significance of Pharmacogenetics and Pharmacogenomics Research in Current Medical Practice
Current Drug Metabolism Covid-19 Susceptibility and Severity Might be Modified by Vitamin D Status: Theoretical and Practical Considerations
Current Respiratory Medicine Reviews Childhood Hospitalisations for Physical Disease and Risk of Mental Disorders During Adolescence and Early Adulthood
Adolescent Psychiatry 4-(4-((5-Amino-1,3,4-thiadiazol-2-yl)methoxy)phenyl)-1-((5-amino-1,3,4-thiadiazol-2-yl)methyl)-3-benzyl-1H-1,2,4-triazol-5(4H)-one: Synthesis, Characterization and Computational Studies
Letters in Organic Chemistry Maternal Vitamin D Status and Development of Asthma and Allergy in Early Childhood
Mini-Reviews in Medicinal Chemistry Cosignaling Complexity Gets More Convoluted: The Emerging Importance of the B7-Like Butyrophilin Family of Immune Regulators
Current Immunology Reviews (Discontinued) Evolving Larger: Dosing Anti-Tuberculosis (TB) Drugs in an Obese World
Current Pharmaceutical Design Bioactive N-Phenylimidazole Derivatives
Current Chemical Biology HIV Type 1 Subtype A1 Dominates in Armenia
Current HIV Research Chemoinformatic Analysis of Biologically Active Macrocycles
Current Topics in Medicinal Chemistry The Bacterial lux Reporter System: Applications in Bacterial Localisation Studies
Current Gene Therapy Extending the Clinical Horizons of Mucosal Bacterial Vaccines: Current Evidence and Future Prospects
Current Drug Targets ATP Synthase Inhibitors as Anti-tubercular Agents: QSAR Studies in Novel Substituted Quinolines
Current Topics in Medicinal Chemistry Role of Cytokines in Chlamydia trachomatis Protective Immunity and Immunopathology
Current Pharmaceutical Design Synthesis, Antimycobacterial Activities and Phototoxic Evaluation of 5H-thiazolo[3,2-a]quinoline-4-carboxylic Acid Derivatives
Medicinal Chemistry Resistant TB: Newer Drugs and Community Approach
Recent Patents on Anti-Infective Drug Discovery Development of Antibacterial Drugs by Targeting Toll-Like Receptors
Current Topics in Medicinal Chemistry Human Tuberculosis I. Epidemiology, Diagnosis and Pathogenetic Mechanisms
Current Medicinal Chemistry Design, Synthesis and Antimycobacterial Activity of Some New Pyridazine Derivatives: Bis-pyridazine. Part IV<sup>12-14</sup>
Infectious Disorders - Drug Targets Mycobacterium tuberculosis Treatment Modalities and Recent Insights
Current Drug Delivery